Back to search
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Refractory B-Cell NHL
Relapsed B-cell NHL
Clinicaltrials.gov:
EU CTIS:
#2023-509258-71-00
Other:
#88998377LYM1001
Subscribe or share this trial
Trials at a glance
Status
Enrollment complete
Condition
Lymphoma, Non-Hodgkin
Refractory B-Cell NHL
Relapsed B-cell NHL
Trial type
Interventional
Trial phase
Phase 1
Investigational
product
product
JNJ-88998377
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
May 28, 2024
Trial end date
February 19, 2029
CT.gov ID
#NCT06470438
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The main purpose of this study is to characterize safety and to determine the recommended
phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to further assess the
safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).
Primary outcome measures
- Parts A and B: Number of Participants with Adverse Events (AEs)
- Part A: Number of Participants with Dose Limiting Toxicity (DLTs)
Secondary outcome measures
- Plasma Concentration of JNJ-88998377
- Area Under the Plasma Concentration Versus Time Curve During A Dosing Interval (τ) At Steady-State of JNJ-88998377
- Maximum Plasma Concentration (Cmax) of JNJ-88998377
- Minimum Plasma Drug Concentration (Cmin) of JNJ-88998377
- Percentage of Participants With Overall Response (OR)
- Time to Response (TTR)
- Duration of Response (DOR)
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
